Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Change in Cash: 2009-2025

Historic Change in Cash for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to -$253.0 million.

  • UNITED THERAPEUTICS's Change in Cash fell 227.65% to -$253.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 147.92%. This contributed to the annual value of $489.5 million for FY2024, which is 98.58% up from last year.
  • UNITED THERAPEUTICS's Change in Cash amounted to -$253.0 million in Q3 2025, which was up 17.54% from -$306.8 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Change in Cash ranged from a high of $202.7 million in Q1 2025 and a low of -$306.8 million during Q2 2025.
  • For the 3-year period, UNITED THERAPEUTICS's Change in Cash averaged around $34.4 million, with its median value being $100.0 million (2023).
  • Within the past 5 years, the most significant YoY rise in UNITED THERAPEUTICS's Change in Cash was 1,885.71% (2023), while the steepest drop was 431.49% (2023).
  • Over the past 5 years, UNITED THERAPEUTICS's Change in Cash (Quarterly) stood at -$13.7 million in 2021, then spiked by 59.12% to -$5.6 million in 2022, then surged by 1,885.71% to $100.0 million in 2023, then spiked by 43.30% to $143.3 million in 2024, then plummeted by 227.65% to -$253.0 million in 2025.
  • Its Change in Cash was -$253.0 million in Q3 2025, compared to -$306.8 million in Q2 2025 and $202.7 million in Q1 2025.